Physician profile
Henry Diaz
NPI 1154376952
$13,031.41
in general payments reported to CMS, 2019-2025
22 companies · $2,921 in 2025
The $2,921 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,657 · 2020: $713 · 2021: $1,278 · 2022: $1,534 · 2023: $1,865 · 2024: $3,065 · 2025: $2,921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,851 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,850.54 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $3,424.18 | 2022-2025 | Winrevair, Pneumovax 23, Verquvo |
| Boston Scientific Corporation | $1,886.89 | 2019-2025 | Watchman Flx, Emblem Mri S-Icd, Resonate El Icd Vr |
| Janssen Pharmaceuticals, INC | $1,704.92 | 2019-2024 | Xarelto, Invokana |
| Medtronic, INC. | $1,227.03 | 2019-2025 | Micra, Symplicity G3, Onyx Frontier |
| Boehringer Ingelheim Pharmaceuticals, INC. | $821.77 | 2021-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $782.03 | 2019-2025 | Lifevest |
| Abbott Laboratories | $616.89 | 2019-2025 | Gallant, Aveir, Assurity |
| Astrazeneca Pharmaceuticals Lp | $534.37 | 2019-2024 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $402.98 | 2019-2024 | |
| Pbg Puerto Rico LLC | $377.56 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $303.86 | 2019-2025 | Eliquis |
| Novartis Pharmaceuticals Corporation | $209.22 | 2019-2025 | |
| Edwards Lifesciences Corporation | $196.56 | 2023-2025 | Pascal, Sapien 3 Ultra Resilia |
| Scpharmaceuticals INC. | $141.05 | 2025 | |
| Bard Peripheral Vascular, INC. | $123.89 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $91.48 | 2023-2025 | Repatha, Repatha |
| Lantheus Medical Imaging, INC. | $41.80 | 2019-2020 | |
| Gilead Sciences, INC. | $39.67 | 2023 | |
| Bayer Puerto Rico INC. | $32.47 | 2025 | Kerendia |
| Pfizer Pharmaceuticals LLC | $31.52 | 2019 | |
| Cardinal Health P.R. 120 INC | $23.44 | 2019 | |
| Chiesi USA, INC. | $17.83 | 2025 | Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.